+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Hemophilia Treatment Market - Global Industry Analysis (2019 - 2021) - Growth Trends and Market Forecast (2022 - 2027)

  • PDF Icon

    Report

  • 196 Pages
  • May 2022
  • Region: Global
  • Fairfield Market Research
  • ID: 5605425
Globally, the incidence of hemophilia has witnessed an uptick over the past few years. Classified as a rare disease, hemophilia occurs due to the absence/lack of a protein known as a clotting factor. It is divided into three main types namely, Hemophilia A, Hemophilia B, and Acquired Hemophilia. Owing to the increase in the incidence of hemophilia and the growing prevalence of blood clotting diseases in the adult population, healthcare professionals (HCPs) are highly driven to develop novel therapeutics to treat hemophilia. This trend is extremely viable for the global hemophilia treatment market as it has opened sound business opportunities for manufacturers across international markets. In the near future, innovation in hemophilia treatments, development of new procedures, and sound hemophilia awareness programs are poised to strengthen the global hemophilia treatment market, enabling it to reach a total market value of US$ 21, 349 million by 2027.

Key Insights and Trends Across Global Hemophilia Treatment Market


Between 2022 to 2027, the global hemophilia treatment market will grow at a promising CAGR of 5.2% owing to healthy market competition, aggressive pursuit of novel therapeutics, strategic partnerships by market players, and sound government rebates.

On the basis of application, the prophylaxis segment is poised to register the highest growth, reaching a total market valuation of US$ 8 billion by 2027.

Whereas, on the basis of treatment type, the recombinant factor concentrates segment is projected to contribute nearly 40% in terms of value.

Over the forecast period, in terms of treatment indication type, Hemophilia B is predicted to register a robust CAGR of ~6%, while Hemophilia A is expected to lead in terms of the total value generated which is expected to be approximately US$ 15 billion.

Favorable Outlook Towards Novel Therapeutics Set to Open Fresh Revenue Streams


Several advanced hemophilia treatment options have surfaced over the recent past, and various others are towards the last stage of clinical trials. Novel therapeutics viz., extended half-life factor concentrates (FVIII/FIX), hemophilia gene therapy, targeting of natural anticoagulant pathways, and biphasic antibodies, coupled with new clotting factor concentrates (CFCs), have significantly decreased the burden of patient care. Consequently, the demand for new hemophilia treatments has dramatically increased. However, concerns around treatment efficacy and overall cost are projected to restrict the rapid market growth in the coming years - a challenge that is being overcome through government rebates and rigorous R&D initiatives by public and private entities.

North America Sustains Position as Market Leader


North America continues to command the highest market share in the global hemophilia treatment market. It recorded a total market value of US$ 6,481 million in 2022, and by 2027, this market value is poised to reach US$ 7,899 million, growing at a CAGR of 4.0%. In North America, major factors harnessing growth in the global hemophilia treatment market include the presence of key industry players, government rebates, and higher national income. Moreover, the availability of modern treatments at relatively lower prices is expected to enable the Asia Pacific to register a robust CAGR of 7.2% over the assessment period.

Major Market Players


Some of the prominent market player in the global hemophilia treatment market include Pfizer Inc, Medexus Pharmaceuticals Inc., Novo Nordisk, Octapharma AG, Takeda Pharmaceuticals Company Ltd., BioMarin Pharmaceuticals, Inc., CSL Behring, Bayer AG, F. Hoffman La Roche Ltd., Grifols S.A., and Sanofi among others.

Table of Contents

1. Executive Summary
1.1. Global Hemophilia Treatment Market Outlook, 2019 - 2027 (US$ Million)
1.2. Global Hemophilia Treatment Market Incremental Opportunity, 2022- 2027 (US$ Million)
1.3. Key Industry Trends
2. Market Overview
2.1. Market Definitions and Segmentations
2.2. Market Dynamics
2.2.1. Market Drivers
2.2.2. Market Threats
2.2.3. Market Opportunities
2.3. Regulatory Framework
2.4. Value Framework of Clinical Scenarios
2.5. Hemophilia Treatment Centres: Comprehensive Care Model
2.6. Reimbursement Scenario
2.7. COVID 19 Impact Analysis
2.8. Hemophilia Market Landscape
3. Global Hemophilia Treatment Market Outlook, 2019 - 2027
3.1. Global Hemophilia Treatment Market Outlook, By Treatment Type, 2019 - 2027
3.1.1. Key Highlights
3.1.2. Global Hemophilia Treatment Market Outlook, by Treatment Type, Value (US$ Million), 2019 - 2027
3.1.2.1. Plasma Derived Factor Concentrates
3.1.2.2. Recombinant Factor Concentrates
3.1.2.3. Alternative Coagulation Promoters
3.1.2.4. Others
3.1.3. Global Hemophilia Treatment Market Share and BPS Analysis, by Treatment Type, Value, 2022 and 2027
3.1.4. Global Hemophilia Treatment Market Attractiveness Analysis, by Treatment Type, Value, 2022 - 2027
3.2. Global Hemophilia Treatment Market Outlook, By Indication Type, 2019 - 2027
3.2.1. Key Highlights
3.2.2. Global Hemophilia Treatment Market Outlook, by Indication Type, Value (US$ Million), 2019 - 2027
3.2.2.1. Hemophilia A
3.2.2.2. Hemophilia B
3.2.2.3. Acquired Hemophilia
3.2.3. Global Hemophilia Treatment Market Share and BPS Analysis, by Indication Type, Value, 2022 and 2027
3.2.4. Global Hemophilia Treatment Market Attractiveness Analysis, by Indication Type, Value, 2022 - 2027
3.3. Global Hemophilia Treatment Market Outlook, By Application, 2019 - 2027
3.3.1. Key Highlights
3.3.2. Global Hemophilia Treatment Market Outlook, by Application, Value (US$ Million), 2019 - 2027
3.3.2.1. Prophylaxis
3.3.2.2. On Demand
3.3.2.3. Surgery
3.3.2.4. Immune Tolerance Induction (ITI)
3.3.2.5. Others
3.3.3. Global Hemophilia Treatment Market Share and BPS Analysis, by Application Value, 2022 and 2027
3.3.4. Global Hemophilia Treatment Market Attractiveness Analysis, by Application, Value 2022 - 2027
3.4. Global Hemophilia Treatment Market Outlook, By Region, 2019 - 2027
3.4.1. Key Highlights
3.4.2. Global Hemophilia Treatment Market Outlook, by Region, Value (US$ Million), 2019 - 2027
3.4.2.1. North America
3.4.2.2. Europe
3.4.2.3. Asia Pacific
3.4.2.4. Rest of the World
3.4.3. Global Hemophilia Treatment Market Share and BPS Analysis, by Region, Value, 2022 and 2027
3.4.4. Global Hemophilia Treatment Market Attractiveness Analysis, by Region, Value, 2022 - 2027
4. North America Hemophilia Treatment Market Outlook, 2019 - 2027
4.1. North America Hemophilia Treatment Market Outlook, By Treatment Type, 2019 - 2027
4.1.1. Key Highlights
4.1.2. North America Hemophilia Treatment Market Outlook, by Country, Value (US$ Million), 2019 - 2027
4.1.2.1. U.S.
4.1.2.2. Canada
4.1.3. North America Hemophilia Treatment Market Outlook, by Treatment Type, Value (US$ Million), 2019 - 2027
4.1.3.1. Plasma Derived Factor Concentrates
4.1.3.2. Recombinant Factor Concentrates
4.1.3.3. Alternative Coagulation Promotors
4.1.3.4. Others
4.1.4. North America Hemophilia Treatment Market Share and BPS Analysis, by Treatment Type, Value, 2022 and 2027
4.1.5. North America Hemophilia Treatment Market Attractiveness Analysis, by Treatment Type, Value, 2022 - 2027
4.2. North America Hemophilia Treatment Market Outlook, By Indication Type, 2019 - 2027
4.2.1. Key Highlights
4.2.2. North America Hemophilia Treatment Market Outlook, by Indication Type, Value (US$ Million), 2019 - 2027
4.2.2.1. Hemophilia A
4.2.2.2. Hemophilia B
4.2.2.3. Acquired Hemophilia
4.2.3. North America Hemophilia Treatment Market Share and BPS Analysis, by Indication Value, 2022 and 2027
4.2.4. North America Hemophilia Treatment Market Attractiveness Analysis, by Indication Type Value, 2022 - 2027
4.3. North America Hemophilia Treatment Market Outlook, By Application, 2019 - 2027
4.3.1. Key Highlights
4.3.2. North America Hemophilia Treatment Market Outlook, by Application, Value (US$ Million) 2019 - 2027
4.3.2.1. Prophylaxis
4.3.2.2. On Demand
4.3.2.3. Surgery
4.3.2.4. Immune Tolerance Induction (ITI)
4.3.2.5. Others
4.3.3. North America Hemophilia Treatment Market Share and BPS Analysis, by Application, Value, 2022 and 2027
4.3.4. North America Hemophilia Treatment Market Attractiveness Analysis, by Application, Value, 2022 - 2027
5. Europe Hemophilia Treatment Market Outlook, 2019 - 2027
5.1. Europe Hemophilia Treatment Market Outlook, By Treatment Type, 2019 - 2027
5.1.1. Key Highlights
5.1.2. Europe Hemophilia Treatment Market Outlook, by Country, Value (US$ Million), 2019 - 2027
5.1.2.1. U.K.
5.1.2.2. France
5.1.2.3. Germany
5.1.2.4. Italy
5.1.2.5. Spain
5.1.2.6. Rest of Europe
5.1.3. Europe Hemophilia Treatment Market Outlook, by Treatment Type, Value (US$ Million), 2019 - 2027
5.1.3.1. Plasma Derived Factor Concentrates
5.1.3.2. Recombinant Factor Concentrates
5.1.3.3. Alternative Coagulation Promotors
5.1.3.4. Others
5.1.4. Europe Hemophilia Treatment Market Share and BPS Analysis, by Treatment Type, Value, 2022 and 2027
5.1.5. Europe Hemophilia Treatment Market Attractiveness Analysis, by Treatment Type, Value, 2022 - 2027
5.2. Europe Hemophilia Treatment Market Outlook, By Indication Type, 2019 - 2027
5.2.1. Key Highlights
5.2.2. Europe Hemophilia Treatment Market Outlook, by Indication Type, Value (US$ Million), 2019 - 2027
5.2.2.1. Hemophilia A
5.2.2.2. Hemophilia B
5.2.2.3. Acquired Hemophilia
5.2.3. Europe Hemophilia Treatment Market Share and BPS Analysis, by Indication Value, 2022 and 2027
5.2.4. Europe Hemophilia Treatment Market Attractiveness Analysis, by Indication Type Value, 2022 - 2027
5.3. Europe Hemophilia Treatment Market Outlook, By Application, 2019 - 2027
5.3.1. Key Highlights
5.3.2. Europe Hemophilia Treatment Market Outlook, by Application, Value (US$ Million) 2019 - 2027
5.3.2.1. Prophylaxis
5.3.2.2. On Demand
5.3.2.3. Surgery
5.3.2.4. Immune Tolerance Induction (ITI)
5.3.2.5. Others
5.3.3. Europe Hemophilia Treatment Market Share and BPS Analysis, by Application, Value, 2022 and 2027
5.3.4. Europe Hemophilia Treatment Market Attractiveness Analysis, by Application, Value, 2022 - 2027
6. Asia Pacific Hemophilia Treatment Market Outlook, 2019 - 2027
6.1. Asia Pacific Hemophilia Treatment Market Outlook, By Treatment Type, 2019 - 2027
6.1.1. Key Highlights
6.1.2. Asia Pacific Hemophilia Treatment Market Outlook, by Country, Value (US$ Million), 2019 - 2027
6.1.2.1. India
6.1.2.2. Japan
6.1.2.3. China
6.1.2.4. Australia
6.1.2.5. Rest of Asia Pacific
6.1.3. Asia Pacific Hemophilia Treatment Market Outlook, by Treatment Type, Value (US$ Million), 2019 - 2027
6.1.3.1. Plasma Derived Factor Concentrates
6.1.3.2. Recombinant Factor Concentrates
6.1.3.3. Alternative Coagulation Promotors
6.1.3.4. Others
6.1.4. Asia Pacific Hemophilia Treatment Market Share and BPS Analysis, by Treatment Type, Value, 2022 and 2027
6.1.5. Asia Pacific Hemophilia Treatment Market Attractiveness Analysis, by Treatment Type, Value, 2022 - 2027
6.2. Asia Pacific Hemophilia Treatment Market Outlook, By Indication Type, 2019 - 2027
6.2.1. Key Highlights
6.2.2. Asia Pacific Hemophilia Treatment Market Outlook, by Indication Type, Value (US$ Million), 2019 - 2027
6.2.2.1. Hemophilia A
6.2.2.2. Hemophilia B
6.2.2.3. Acquired Hemophilia
6.2.3. Asia Pacific Hemophilia Treatment Market Share and BPS Analysis, by Indication Value, 2022 and 2027
6.2.4. Asia Pacific Hemophilia Treatment Market Attractiveness Analysis, by Indication Type Value, 2022 - 2027
6.3. Asia Pacific Hemophilia Treatment Market Outlook, By Application, 2019 - 2027
6.3.1. Key Highlights
6.3.2. Asia Pacific Hemophilia Treatment Market Outlook, by Application, Value (US$ Million) 2019 - 2027
6.3.2.1. Prophylaxis
6.3.2.2. On Demand
6.3.2.3. Surgery
6.3.2.4. Immune Tolerance Induction (ITI)
6.3.2.5. Others
6.3.3. Asia Pacific Hemophilia Treatment Market Share and BPS Analysis, by Application, Value, 2022 and 2027
6.3.4. Asia Pacific Hemophilia Treatment Market Attractiveness Analysis, by Application, Value, 2022 - 2027
7. Rest of the World Hemophilia Treatment Market Outlook, 2019 - 2027
7.1. Rest of the World Hemophilia Treatment Market Outlook, By Treatment Type, 2019 - 2027
7.1.1. Key Highlights
7.1.2. Rest of the World Hemophilia Treatment Market Outlook, by Country, Value (US$ Million), 2019 - 2027
7.1.2.1. Latin America
7.1.2.2. Middle East & Africa
7.1.3. Rest of the World Hemophilia Treatment Market Outlook, by Treatment Type, Value (US$ Million), 2019 - 2027
7.1.3.1. Plasma Derived Factor Concentrates
7.1.3.2. Recombinant Factor Concentrates
7.1.3.3. Alternative Coagulation Promotors
7.1.3.4. Others
7.1.4. Rest of the World Hemophilia Treatment Market Share and BPS Analysis, by Treatment Type, Value, 2022 and 2027
7.1.5. Rest of the World Hemophilia Treatment Market Attractiveness Analysis, by Treatment Type, Value, 2022 - 2027
7.2. Rest of the World Hemophilia Treatment Market Outlook, By Indication Type, 2019 - 2027
7.2.1. Key Highlights
7.2.2. Rest of the World Hemophilia Treatment Market Outlook, by Indication Type, Value (US$ Million), 2019 - 2027
7.2.2.1. Hemophilia A
7.2.2.2. Hemophilia B
7.2.2.3. Acquired Hemophilia
7.2.3. Rest of the World Hemophilia Treatment Market Share and BPS Analysis, by Indication Value, 2022 and 2027
7.2.4. Rest of the World Hemophilia Treatment Market Attractiveness Analysis, by Indication Type Value, 2022 - 2027
7.3. Rest of the World Hemophilia Treatment Market Outlook, By Application, 2019 - 2027
7.3.1. Key Highlights
7.3.2. Rest of the World Hemophilia Treatment Market Outlook, by Application, Value (US$ Million) 2019 - 2027
7.3.2.1. Prophylaxis
7.3.2.2. On Demand
7.3.2.3. Surgery
7.3.2.4. Immune Tolerance Induction (ITI)
7.3.2.5. Others
7.3.3. Rest of the World Hemophilia Treatment Market Share and BPS Analysis, by Application, Value, 2022 and 2027
7.3.4. Rest of the World Hemophilia Treatment Market Attractiveness Analysis, by Application, Value, 2022 - 2027
8. Competitive Landscape
8.1. Market Share Analysis, 2021
8.2. Company Profiles
8.2.1. Bayer AG
8.2.1.1. Company overview
8.2.1.2. Financial performance
8.2.1.3. Product Portfolio
8.2.1.4. Pipeline Analysis
Above details will include, but not be limited to below list of companies based on availability
8.2.2. BioMarin Pharmaceuticals, Inc.
8.2.3. F. Hoffman La Roche Ltd.
8.2.4. Grifols S.A.
8.2.5. Sanofi
8.2.6. Takeda Pharmaceuticals Company Ltd.
8.2.7. CSL Behring
8.2.8. Medexus Pharmaceuticals Inc.
8.2.9. Novo Nordisk
8.2.10. Octapharma AG
8.2.11. Pfizer Inc.
9. Appendix
9.1. Research Methodology
9.2. Report Specific Research Approach

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Bayer AG
  • BioMarin Pharmaceuticals, Inc.
  • F. Hoffman La Roche Ltd.
  • Grifols S.A.
  • Sanofi
  • Takeda Pharmaceuticals Company Ltd.
  • CSL Behring
  • Medexus Pharmaceuticals Inc.
  • Novo Nordisk
  • Octapharma AG
  • Pfizer Inc.

Methodology

Loading
LOADING...